Syngene International
SYNGENE · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar Shaw · MD: Jonathan Hunt · Listing date: Aug. 11, 2015 · Employees: 5437 · Bangalore · http://www.syngeneintl.com

Stock Price vs Company Growth
1d
2.2%
1w
1.8%
1m
15.1%
3m
2.5%
6m
25.5%
1y
24.7%
5y
4.2%
10y
9.6%
all
10.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 459 2.2%
380
518
Company Overview

Sales
3,739 Cr
Growth: 2.8%
Profit after Tax
317 Cr
Growth: -10.1%
Mid Cap
18,539 Cr
P/E: 58.7x
Industry P/E: 30.4x
Fundamentals

Sales (Cr) ₹ 3,739
Growth 2.8%
EBITDA 24.6%
P/S 5.0x
Dividend 0.2%
P/E 58.7x
Book Value ₹ 120
PEG Ratio 20.8x
ROE 6.5%
P/B 3.8x
Shareholding Pattern

Institutions
Government Pension Fund Global
1.14 %
Uti-Mid Cap Fund
1.03 %
Qualified Institutional Buyer
0.15 %
Promoters
Biocon Limited
70.1 %
Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha)
0.32 %
Yamini R Mazumdar
0.01 %
Others
Increase    Decrease    No change
Company Profile Detailed

The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.
Investors (435)
Followers (15)